Focal cartilage defects rarely need surgery as the first step

Most patients facing a focal knee cartilage defect ask the same question: does this mean surgery? For many, the honest answer is no — not as the first step, and often not at all.

Cartilage has no blood supply of its own. That avascular nature means it cannot mount the self-repair response that bone or soft tissue can; a defect does not simply settle with rest and time. Focal lesions above roughly 1 cm in size tend to enlarge progressively, and without structured treatment they carry a meaningful risk of progressing to osteoarthritis. Waiting until symptoms become severe enough to cross a surgical threshold typically means a larger area of damage to address and fewer options available.

The clinical window for intervention — defects roughly 1–6 cm² in a joint where the surrounding cartilage remains reasonably intact — is precisely where a non-surgical injectable scaffold pathway can work most effectively. ChondroFiller® liquid is a CE-marked Class III medical device: an injectable collagen scaffold placed under ultrasound guidance as an outpatient appointment, with no general anaesthetic and no theatre admission required. It is positioned as a first-line option for eligible patients because it can achieve clinically meaningful outcomes while keeping the procedural burden, recovery time, and risk substantially lower than any surgical route.

How it does that — the biology the scaffold sets in motion — is covered in the next section.

How ChondroFiller works inside the joint

The collagen solution itself contains no donor cells — that distinction matters. ChondroFiller® liquid is an acellular scaffold, meaning its role is not to deliver cartilage-forming cells but to create the structural conditions in which the patient's own cells can do that work.

Once placed into the defect under ultrasound guidance, the liquid sets quickly: within 3–5 minutes it self-gels and bonds with fibrin at the lesion site, forming a stable, three-dimensional matrix that fills and conforms to the defect. Think of it as a temporary framework — not the finished tissue, but the architecture that makes new tissue possible.

From that point, biology takes over through a process called acellular matrix-induced chondrogenesis. The gelled scaffold acts as a chemotactic signal, drawing progenitor cells inward from the surrounding synovium and subchondral bone. Within days to weeks, those recruited cells begin migrating into the matrix; over the following months they differentiate toward chondrocytes — the specialised cells responsible for maintaining articular cartilage — and progressively lay down new tissue as the scaffold is gradually resorbed. By 1–2 years post-treatment, the scaffold has been completely replaced by the patient's own regenerated tissue.

The benefit is not only symptomatic. Post-treatment MRI in treated joints has shown measurable structural changes: reduction in bone marrow oedema, decreased periarticular effusion, and visible preservation of joint space — objective radiological evidence that sits alongside the patient-reported outcome improvements.

What the injection appointment involves

Attending for the injection itself is a straightforward outpatient appointment. The collagen scaffold is delivered under real-time ultrasound guidance — no theatre, no general anaesthetic, and no surgical incisions are involved. There are no staged procedures and no separate appointments for tissue harvesting: unlike two-stage techniques such as ACI/MACI, the injectable route is complete in a single clinic visit.

Before treatment is confirmed, pre-injection MRI of the joint is a core part of the workup. Imaging establishes defect location, depth, and — critically — the condition of the underlying subchondral bone, which determines whether the scaffold has an adequate base to work from. At MSK Doctors' Sleaford and Grantham sites, AI-assisted MRI analysis (onMRI™) can support this planning where appropriate, giving consultants a more precisely characterised picture before the needle is placed.

Recovery is substantially lighter than any surgical route. Most patients are back to light activity within one to two weeks. The injectable pathway carries no stated upper age limit and no absolute ceiling on defect size, though subchondral bone quality confirmed on imaging is what determines individual suitability — this is assessed at consultation, not assumed from symptom history alone.

Guide costs for the injectable pathway are confirmed at consultation rather than fixed upfront. Patients across Lincolnshire and the wider East Midlands can book a specialist assessment at mskdoctors.com without needing a GP referral and without the waits typical of NHS pathways.

Clinical outcomes versus microfracture and ACI

Three approaches dominate current practice for symptomatic focal knee cartilage defects: microfracture, autologous chondrocyte implantation (ACI/MACI), and the ChondroFiller® injectable scaffold. IKDC score — a validated patient-reported outcome measuring knee function and symptoms — provides a consistent comparator across all three.

Published data indicate ChondroFiller® achieves approximately 30 points of IKDC improvement over 12 months. ACI/MACI produces comparable gains of 30–35 points. Microfracture generates more variable results that often decline over time. The clinical trajectories are broadly similar for the first two — the difference lies in what each pathway requires to reach that destination.

ACI/MACI demands two separate surgical procedures under general anaesthetic: an initial chondrocyte harvest and a later implantation operation. Complication rates for that route reach up to 17%, and reoperation rates up to 37%. ChondroFiller® achieves equivalent IKDC gains through a single outpatient injection, with a reported complication rate of approximately 0% and a reoperation rate of 3–8%.

Microfracture carries a different limitation. It is typically suited only to defects smaller than 2–4 cm² and produces fibrocartilage — a mechanically inferior substitute for native hyaline cartilage — with reoperation rates reported at up to 41%. ChondroFiller® treats defects up to 6 cm² in a single injectable session, with regenerated tissue quality described as hyaline-like rather than fibrous.

One important caveat: the comparative figures cited here derive principally from a manufacturer-sponsored Clinical Evaluation Report and associated expert analyses. Independent randomised controlled trials directly comparing ChondroFiller® against surgery are limited, and durability data beyond two years remain sparse. A specialist assessment remains the appropriate place to discuss what the evidence does and does not yet establish for an individual patient.

Who is suitable and what the assessment covers

Eligibility for the injectable ChondroFiller® pathway turns primarily on defect characteristics rather than patient demographics. Suitable candidates typically present with a focal, symptomatic cartilage lesion — a localised area of damage rather than diffuse joint-wide osteoarthritis — confirmed on MRI. The distinction matters clinically: in diffuse OA, cartilage loss is widespread rather than contained, and a scaffold-based approach cannot address a joint surface that is uniformly degraded.

Selection typically follows failure of conservative measures. Where physiotherapy, activity modification, and earlier symptom-management approaches have not delivered adequate relief and MRI confirms a focal defect, the ChondroFiller® pathway enters consideration. Subchondral bone integrity is an essential co-factor at this stage: the scaffold requires a structurally sound base from which to recruit the patient's own progenitor cells. Where imaging reveals significant bone loss or osteochondral involvement, the clinical picture shifts — this is assessed at consultation rather than assumed from symptom history alone.

The surgical escalation — Liquid Cartilage™, which pairs the collagen scaffold with mesenchymal stem cell co-delivery — is reserved for cases where defect size or complexity places the lesion beyond what an outpatient injection can adequately address. It is not a first or default choice but a specifically indicated pathway for the subset of patients whose anatomy warrants it. A specialist consultation, with imaging reviewed beforehand, is the appropriate starting point for determining which route fits.

Evidence limits and long-term durability

Five-year and beyond durability data — the kind that anchors long-term surgical decision-making — are not yet available for the ChondroFiller® injectable pathway in the published sources. Strong, consistent evidence exists within the first one to two years of treatment; beyond that window, there is a genuine gap. For a CE-marked Class III device that entered broader clinical use relatively recently, this is where the evidence curve naturally sits — informative rather than complete.

Within that available window, objective imaging adds weight to patient-reported improvements. Post-treatment MRI in treated joints has confirmed reductions in bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space — structural changes that corroborate functional gains rather than relying on questionnaire data alone.

The clinical dataset derives substantially from manufacturer-sponsored evaluations rather than independent randomised trials, and the comparative figures discussed earlier carry that caveat. The relevant additional point is this: given that profile, the injectable pathway earns its first-line position not because its evidence base is exhaustive, but because the risk and patient burden of attempting it first are sufficiently low that proceeding straight to surgery without trying it rarely represents sound clinical reasoning. Longer-term answers will accumulate; the data available today support starting here.